Table 1.
Patient and tumor characteristics of the two cohorts analyzed.
| VUMC (n=252) | TCIA (n=250) | P-value | |
|---|---|---|---|
| VSVZ-contacting (%) | 120 (47.6) | 124 (49.6) | 0.723 |
| Age [years; median (IQR)] | 61.63 [51.93, 69.44] | 59.50 [52.00, 69.00] | 0.324 |
| Tumor volume [median (IQR)] | 30.20 [14.84, 51.77] | 33.09 [17.77, 60.59] | 0.082 |
| KPS (%) | <0.001 | ||
| 100-80 | 123 (48.8) | 157 (62.8) | |
| 70-50 | 111 (44.0) | 43 (17.2) | |
| 40-10 | 18 (7.1) | 10 (4.0) | |
| Unknown | 0 (0.0) | 40 (16.0) | |
| IDH1/2 mutation status (%) | 0.001 | ||
| WT | 222 (88.1) | 189 (75.6) | |
| Mutant | 8 (3.2) | 12 (4.8) | |
| Unknown | 22 (8.7) | 49 (19.6) | |
| MGMT promoter methylation status (%) | <0.001 | ||
| Unmethylated | 166 (65.9) | 82 (32.8) | |
| Methylated | 55 (21.8) | 82 (32.8) | |
| Unknown | 31 (12.3) | 86 (34.4) | |
| Temozolomide (%) | 202 (80.2) | 165 (66.0) | 0.001 |
| Radiotherapy (%) | 223 (88.5) | 188 (75.2) | <0.001 |
| Extent of Resection (%) | |||
| Biopsy | 17 (6.7) | N/A | |
| STR | 126 (50.0) | N/A | |
| NTR | 64 (25.4) | N/A | |
| GTR | 45 (17.9) | N/A |